Free Trial
NYSE:NSPR

InspireMD (NSPR) Stock Price, News & Analysis

$3.39
+0.41 (+13.76%)
(As of 07/26/2024 ET)
Today's Range
$2.96
$3.42
50-Day Range
$2.28
$3.39
52-Week Range
$1.81
$3.85
Volume
100,953 shs
Average Volume
26,636 shs
Market Capitalization
$84.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.85

InspireMD MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.1% Upside
$4.85 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of InspireMD in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

753rd out of 936 stocks

Surgical & Medical Instruments Industry

81st out of 101 stocks

NSPR stock logo

About InspireMD Stock (NYSE:NSPR)

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

NSPR Stock Price History

NSPR Stock News Headlines

This TSLA short trade is on a nine win hot streak
Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.
InspireMD earnings preview: what Wall Street is expecting
InspireMD, Inc. (NSPR)
This TSLA short trade is on a nine win hot streak
Most Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.
Preview: InspireMD's Earnings
See More Headlines
Receive NSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/26/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.85
High Stock Price Target
$5.20
Low Stock Price Target
$4.50
Potential Upside/Downside
+43.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,920,000.00
Net Margins
-350.35%
Pretax Margin
-349.34%

Debt

Sales & Book Value

Annual Sales
$6.20 million
Book Value
$1.83 per share

Miscellaneous

Free Float
17,521,000
Market Cap
$84.51 million
Optionable
Optionable
Beta
0.96
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Marvin L. Slosman (Age 60)
    President, CEO & Director
    Comp: $843.83k
  • Mr. Craig Shore (Age 63)
    CFO, Chief Administrative Officer, Secretary & Treasurer
    Comp: $613.49k
  • Mr. Shane Thomas Gleason (Age 49)
    Chief Commercial Officer
    Comp: $486.04k
  • Mr. Andrea Tommasoli (Age 52)
    Chief Operating Officer
    Comp: $359.27k
  • Mr. Amir Kohen
    Vice President of Finance & Human Resources
  • Dr. Patrick A. Verta DVM (Age 66)
    M.D., MS Stat, Executive Vice President of Clinical & Medical Affairs
  • Mr. Pete Ligotti
    Executive VP & GM of North America
  • Dr. Sol J. Barer Ph.D. (Age 77)
    Special Advisor to the Board
    Comp: $13.92k

NSPR Stock Analysis - Frequently Asked Questions

How have NSPR shares performed this year?

InspireMD's stock was trading at $2.81 on January 1st, 2024. Since then, NSPR shares have increased by 20.6% and is now trading at $3.39.
View the best growth stocks for 2024 here
.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.06. The company earned $1.51 million during the quarter, compared to analyst estimates of $1.38 million. InspireMD had a negative trailing twelve-month return on equity of 55.12% and a negative net margin of 350.35%.

Who are InspireMD's major shareholders?

InspireMD's top institutional shareholders include Rosalind Advisors Inc. (10.08%). Insiders that own company stock include Gary S Roubin and Paul Stuka.
View institutional ownership trends
.

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA), Acasti Pharma (ACST) and AcelRx Pharmaceuticals (ACRX).

This page (NYSE:NSPR) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners